NCT03670030View on ClinicalTrials.gov

A Study to testABI-009 in Patients With Metastatic, Unresectable, Low or Intermediate Grade Neuroendocrine Tumors of the Lung or Gastroenteropancreatic System

PHASE2TerminatedINTERVENTIONAL
Enrollment

5

Participants

Timeline

Start Date

November 5, 2018

Primary Completion Date

January 1, 2021

Study Completion Date

February 26, 2021

Conditions
Neuroendocrine Tumors
Interventions
DRUG

ABI-009

rapamycin protein-bound nanoparticles for injectable suspension (albumin bound)

Trial Locations (1)

70121

Ochsner Clinic Foundation, New Orleans

Sponsors

Collaborators (1)

Aadi Bioscience, Inc.
All Listed Sponsors
collaborator

Aadi Bioscience, Inc.

INDUSTRY

lead

Robert Ramirez

OTHER